Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00176020
Status:
UNKNOWN
Last Update Posted:
2006-03-15
First Post:
2005-09-12
Brief Title:
Nicotinic Acid - Pharmacokinetics Pharmacodynamics Receptor Expression
Sponsor:
Heidelberg University
Organization:
Heidelberg University
Study Overview
Official Title:
Double-Blind Randomized Placebo-Controlled Single-Center 2 Treatment 3-Way Crossover Study to Investigate the Pharmacodynamics Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 Mg Nicotinic Acid as Tablets in Healthy Subjects
Status:
UNKNOWN
Status Verified Date:
2005-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study will be a double-blind randomized placebo-controlled single-center 2 treatment 3--way crossover Subjects will be randomly allocated to a treatment sequence - AAB ABA or BAA The two treatments will be
Treatment A 500 mg nicotinic acid NiacorR
Treatment B NiacorR Placebo
Each trial period will last one day there will be a wash-out period of at least 2 days between each trial period Five to seven days after study day 1 of trial period 3 there will be a final safety examination
Treatment A 500 mg nicotinic acid NiacorR
Treatment B NiacorR Placebo
Each trial period will last one day there will be a wash-out period of at least 2 days between each trial period Five to seven days after study day 1 of trial period 3 there will be a final safety examination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| K115 | None | None | None |